The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Biomarker; Pharmacodynamics
- 11 Sep 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 03 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2017.